How big is Harmony Biosciences Holdings, Inc.?

As of Jun 18, Harmony Biosciences Holdings, Inc. has a market capitalization of 1,864.57 million, with net sales of 744.85 million and a net profit of 152.72 million over the last four quarters.

Market Cap: As of Jun 18, Harmony Biosciences Holdings, Inc. has a market capitalization of 1,864.57 million, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Harmony Biosciences reported net sales of 744.85 million and a net profit of 152.72 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 659.15 million, while total assets were reported at 999.20 million.

What does Harmony Biosciences Holdings, Inc. do?

Harmony Biosciences Holdings, Inc. is a pharmaceutical company specializing in therapies for central nervous system disorders, particularly narcolepsy. As of March 2025, it reported net sales of $185 million and a net profit of $46 million, with a market cap of approximately $1.86 billion.

Overview:<BR>Harmony Biosciences Holdings, Inc. is a pharmaceutical company focused on therapies for patients suffering from central nervous system disorders, particularly narcolepsy, and operates within the Pharmaceuticals & Biotechnology industry in the small-cap market.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 185 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: 46 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 1,864.57 Million (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 13.00<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.42<BR>- Return on Equity: 21.20%<BR>- Price to Book: 2.59<BR><BR>Contact Details:<BR>- Address: 630 W Germantown Pike, Suite 215, PLYMOUTH MEETING PA: 19462<BR>- Tel: 1 484 5399800<BR>- Fax: 1 302 6555049

Should I buy, sell or hold Harmony Biosciences Holdings, Inc.?

Is Harmony Biosciences Holdings, Inc. overvalued or undervalued?

As of August 5, 2025, Harmony Biosciences Holdings, Inc. has a very attractive valuation with a low P/E ratio of 13 and favorable EV to EBITDA of 7.96, despite underperforming the S&P 500 with a one-year return of -14.89%.

As of 5 August 2025, the valuation grade for Harmony Biosciences Holdings, Inc. has moved from attractive to very attractive, indicating a strong improvement in its valuation outlook. The company appears to be undervalued, with a P/E ratio of 13, significantly lower than the peer average of 11.40 for similar companies. Additionally, the EV to EBITDA ratio stands at 7.96, which is also favorable compared to peers like Prestige Consumer Healthcare, Inc. with an EV to EBITDA of 11.55. The PEG ratio of 3.11 suggests that the stock may be undervalued relative to its growth prospects.<BR><BR>In comparison to its peers, Harmony Biosciences shows a robust ROCE of 46.44% and ROE of 21.20%, further supporting its valuation stance. However, the company's stock has underperformed against the S&P 500 over multiple periods, with a one-year return of -14.89% compared to the S&P 500's 17.14%, indicating a need for caution despite the attractive valuation metrics.

Is Harmony Biosciences Holdings, Inc. technically bullish or bearish?

As of October 3, 2025, Harmony Biosciences Holdings, Inc. is in a bearish trend, indicated by negative MACD readings, bearish Bollinger Bands, and underperformance against the S&P 500, with a year-to-date return of -22.73% compared to the S&P 500's 14.18%.

As of 3 October 2025, the technical trend for Harmony Biosciences Holdings, Inc. has changed from mildly bearish to bearish. The current stance is bearish, with key indicators supporting this view including bearish MACD readings on both weekly and monthly time frames, bearish Bollinger Bands, and bearish moving averages on the daily chart. The Dow Theory indicates a mildly bearish trend on a monthly basis, while the KST and OBV are also bearish on both weekly and monthly time frames. <BR><BR>In terms of performance, the stock has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -22.73% compared to the S&P 500's 14.18%, and a three-year return of -44.74% versus the S&P 500's 82.57%.